Cover Image
市場調查報告書

第二型糖尿病:開發中產品分析

Type 2 Diabetes - Pipeline Review, H1 2017

出版商 Global Markets Direct 商品編碼 232774
出版日期 內容資訊 英文 1100 Pages
訂單完成後即時交付
價格
Back to Top
第二型糖尿病:開發中產品分析 Type 2 Diabetes - Pipeline Review, H1 2017
出版日期: 2017年05月30日 內容資訊: 英文 1100 Pages
簡介

第二型糖尿病是慢性疾病,也是最常見的糖尿病。特徵是血糖值高,身體抗拒胰島素,而漸漸無法產生足夠的胰島素。

本報告提供第二型糖尿病的治療藥開發平台現狀及最新更新的各開發階段比較分析,提供您企業和研究機關開發中的治療藥,治療藥評估,後期階段及中止的計劃等相關資訊,以及新的新聞和發表。

簡介

第二型糖尿病概要

治療藥的開發

第二型糖尿病:企業開發中的治療藥

第二型糖尿病:大學/機關研究中的治療藥

第二型糖尿病:開發中產品概況

第二型糖尿病:企業開發中的產品

第二型糖尿病:大學/機關研究中的產品

第二型糖尿病的治療藥的開發企業

第二型糖尿病:治療藥的評估

藥物簡介

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC9358IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Type 2 Diabetes - Pipeline Review, H1 2017, provides an overview of the Type 2 Diabetes (Metabolic Disorders) pipeline landscape.

Type 2 diabetes is a chronic condition and is the most common form of diabetes. High levels of glucose are a characteristic feature. The body might become resistant to insulin or may not produce enough amounts. Due to abnormal insulin functioning, glucose is concentrated in the blood leading to elevated levels and hence causing type 2 diabetes. Symptoms include fatigue, weight issues, vision deficits and various other effects. Risk factors include family history, age, obesity, physical inactivity and high blood pressure. This condition is handled by lifestyle alterations and regular medications.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Type 2 Diabetes - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Type 2 Diabetes (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Type 2 Diabetes (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Type 2 Diabetes and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 14, 1, 25, 68, 64, 5, 250, 75 and 6 respectively. Similarly, the Universities portfolio in Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages comprises 1, 1, 1, 62 and 22 molecules, respectively.

Type 2 Diabetes (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Type 2 Diabetes (Metabolic Disorders).
  • The pipeline guide reviews pipeline therapeutics for Type 2 Diabetes (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Type 2 Diabetes (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Type 2 Diabetes (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Type 2 Diabetes (Metabolic Disorders)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Type 2 Diabetes (Metabolic Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Type 2 Diabetes (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
  • Introduction
  • Type 2 Diabetes - Overview
  • Type 2 Diabetes - Therapeutics Development
  • Type 2 Diabetes - Therapeutics Assessment
  • Type 2 Diabetes - Companies Involved in Therapeutics Development
  • Type 2 Diabetes - Drug Profiles
  • Type 2 Diabetes - Dormant Projects
  • Type 2 Diabetes - Discontinued Products
  • Type 2 Diabetes - Product Development Milestones
  • Appendix

List of Tables

  • Number of Products under Development for Type 2 Diabetes, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..2), H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..3), H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..4), H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..5), H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..6), H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..7), H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..8), H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..9), H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..10), H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..11), H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..12), H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..13), H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..14), H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017 (Contd..1), H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017 (Contd..2), H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017 (Contd..3), H1 2017
  • Products under Development by Companies, H1 2017
  • Products under Development by Companies, H1 2017 (Contd..1), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..2), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..3), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..4), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..5), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..6), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..7), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..8), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..9), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..10), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..11), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..12), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..13), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..14), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..15), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..16), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..17), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..18), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..19), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..20), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..21), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..22), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..23), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..24), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..25), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..26), H1 2017
  • Products under Development by Universities/Institutes, H1 2017
  • Products under Development by Universities/Institutes, H1 2017 (Contd..1), H1 2017
  • Products under Development by Universities/Institutes, H1 2017 (Contd..2), H1 2017
  • Products under Development by Universities/Institutes, H1 2017 (Contd..3), H1 2017
  • Products under Development by Universities/Institutes, H1 2017 (Contd..4), H1 2017
  • Number of Products by Stage and Target, H1 2017
  • Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017
  • Number of Products by Stage and Target, H1 2017 (Contd..2), H1 2017
  • Number of Products by Stage and Target, H1 2017 (Contd..3), H1 2017
  • Number of Products by Stage and Target, H1 2017 (Contd..4), H1 2017
  • Number of Products by Stage and Target, H1 2017 (Contd..5), H1 2017
  • Number of Products by Stage and Target, H1 2017 (Contd..6), H1 2017
  • Number of Products by Stage and Target, H1 2017 (Contd..7), H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..2), H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..3), H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..4), H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..5), H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..6), H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..7), H1 2017
  • Number of Products by Stage and Route of Administration, H1 2017
  • Number of Products by Stage and Molecule Type, H1 2017
  • Type 2 Diabetes - Pipeline by 4P Therapeutics LLC, H1 2017
  • Type 2 Diabetes - Pipeline by Addex Therapeutics Ltd, H1 2017
  • Type 2 Diabetes - Pipeline by Adocia, H1 2017
  • Type 2 Diabetes - Pipeline by Advinus Therapeutics Ltd, H1 2017
  • Type 2 Diabetes - Pipeline by Aegis Therapeutics LLC, H1 2017
  • Type 2 Diabetes - Pipeline by AFFiRiS AG, H1 2017
  • Type 2 Diabetes - Pipeline by Alize Pharma SAS, H1 2017
  • Type 2 Diabetes - Pipeline by Allergan Plc, H1 2017
  • Type 2 Diabetes - Pipeline by Alteogen Inc, H1 2017
  • Type 2 Diabetes - Pipeline by Amarantus Bioscience Holdings Inc, H1 2017
  • Type 2 Diabetes - Pipeline by Amgen Inc, H1 2017
  • Type 2 Diabetes - Pipeline by Anchor Therapeutics Inc, H1 2017
  • Type 2 Diabetes - Pipeline by AntriaBio Inc, H1 2017
  • Type 2 Diabetes - Pipeline by Aphios Corp, H1 2017
  • Type 2 Diabetes - Pipeline by Araim Pharmaceuticals Inc, H1 2017
  • Type 2 Diabetes - Pipeline by Arena Pharmaceuticals Inc, H1 2017
  • Type 2 Diabetes - Pipeline by Arisaph Pharmaceuticals Inc, H1 2017
  • Type 2 Diabetes - Pipeline by ArisGen SA, H1 2017
  • Type 2 Diabetes - Pipeline by Astellas Pharma Inc, H1 2017
  • Type 2 Diabetes - Pipeline by AstraZeneca Plc, H1 2017
  • Type 2 Diabetes - Pipeline by AusBio Ltd, H1 2017
  • Type 2 Diabetes - Pipeline by Avadel Pharmaceuticals Plc, H1 2017
  • Type 2 Diabetes - Pipeline by Bayer AG, H1 2017
  • Type 2 Diabetes - Pipeline by Beta-Cell NV, H1 2017
  • Type 2 Diabetes - Pipeline by Betagenon AB, H1 2017
  • Type 2 Diabetes - Pipeline by Betta Pharmaceuticals Co Ltd, H1 2017
  • Type 2 Diabetes - Pipeline by Biocon Ltd, H1 2017
  • Type 2 Diabetes - Pipeline by BioLingus AG, H1 2017
  • Type 2 Diabetes - Pipeline by BioRestorative Therapies Inc, H1 2017
  • Type 2 Diabetes - Pipeline by Biozeus, H1 2017
  • Type 2 Diabetes - Pipeline by Biscayne Pharmaceuticals Inc, H1 2017
  • Type 2 Diabetes - Pipeline by Boehringer Ingelheim GmbH, H1 2017
  • Type 2 Diabetes - Pipeline by Boston Therapeutics Inc, H1 2017
  • Type 2 Diabetes - Pipeline by Braasch Biotech LLC, H1 2017
  • Type 2 Diabetes - Pipeline by Bristol-Myers Squibb Company, H1 2017
  • Type 2 Diabetes - Pipeline by C4X Discovery Holdings PLC, H1 2017
  • Type 2 Diabetes - Pipeline by Cadila Pharmaceuticals Ltd, H1 2017
  • Type 2 Diabetes - Pipeline by Cardax Inc, H1 2017
  • Type 2 Diabetes - Pipeline by Carmot Therapeutics Inc, H1 2017
  • Type 2 Diabetes - Pipeline by Celon Pharma SA, H1 2017
  • Type 2 Diabetes - Pipeline by Chipscreen Biosciences Ltd, H1 2017
  • Type 2 Diabetes - Pipeline by Chong Kun Dang Pharmaceutical Corp, H1 2017
  • Type 2 Diabetes - Pipeline by CJ HealthCare Corp, H1 2017
  • Type 2 Diabetes - Pipeline by CohBar Inc, H1 2017
  • Type 2 Diabetes - Pipeline by Concenter BioPharma Silkim Ltd, H1 2017
  • Type 2 Diabetes - Pipeline by ConjuChem LLC, H1 2017
  • Type 2 Diabetes - Pipeline by Connexios Life Sciences Pvt Ltd, H1 2017
  • Type 2 Diabetes - Pipeline by ConSynance Therapeutics Inc, H1 2017
  • Type 2 Diabetes - Pipeline by Corium International Inc, H1 2017
  • Type 2 Diabetes - Pipeline by CSL Ltd, H1 2017
  • Type 2 Diabetes - Pipeline by CureDM Inc, H1 2017
  • Type 2 Diabetes - Pipeline by CymaBay Therapeutics Inc, H1 2017
  • Type 2 Diabetes - Pipeline by Daewoong Pharmaceutical Co Ltd, H1 2017
  • Type 2 Diabetes - Pipeline by Daiichi Sankyo Company Ltd, H1 2017
  • Type 2 Diabetes - Pipeline by Dance Biopharm Inc, H1 2017
  • Type 2 Diabetes - Pipeline by Delpor Inc, H1 2017
  • Type 2 Diabetes - Pipeline by Diabetology (Products) Ltd, H1 2017
  • Type 2 Diabetes - Pipeline by DiaMedica Therapeutics Inc, H1 2017
  • Type 2 Diabetes - Pipeline by Diamyd Medical AB, H1 2017
  • Type 2 Diabetes - Pipeline by Diasome Pharmaceuticals Inc, H1 2017
  • Type 2 Diabetes - Pipeline by DiscoveryBiomed Inc, H1 2017
  • Type 2 Diabetes - Pipeline by DNJ Pharma Inc, H1 2017
  • Type 2 Diabetes - Pipeline by Dong-A Socio Holdings Co Ltd, H1 2017
  • Type 2 Diabetes - Pipeline by Elcelyx Therapeutics Inc, H1 2017
  • Type 2 Diabetes - Pipeline by Eli Lilly and Company, H1 2017
  • Type 2 Diabetes - Pipeline by Enteris BioPharma Inc, H1 2017
  • Type 2 Diabetes - Pipeline by Enzo Biochem Inc, H1 2017
  • Type 2 Diabetes - Pipeline by Epichem Pty Ltd, H1 2017
  • Type 2 Diabetes - Pipeline by Esperion Therapeutics Inc, H1 2017
  • Type 2 Diabetes - Pipeline by Eternygen GmbH, H1 2017
  • Type 2 Diabetes - Pipeline by Evotec AG, H1 2017
  • Type 2 Diabetes - Pipeline by F. Hoffmann-La Roche Ltd, H1 2017
  • Type 2 Diabetes - Pipeline by Generex Biotechnology Corp, H1 2017
  • Type 2 Diabetes - Pipeline by Genexine Inc, H1 2017
  • Type 2 Diabetes - Pipeline by Genfit SA, H1 2017
  • Type 2 Diabetes - Pipeline by Genmedica Therapeutics SL, H1 2017
  • Type 2 Diabetes - Pipeline by Genovate Biotechnology Co LTD, H1 2017
  • Type 2 Diabetes - Pipeline by Geropharm LLC, H1 2017
  • Type 2 Diabetes - Pipeline by Gilead Sciences Inc, H1 2017
  • Type 2 Diabetes - Pipeline by GlaxoSmithKline Plc, H1 2017
  • Type 2 Diabetes - Pipeline by Glide Pharmaceutical Technologies Ltd, H1 2017
  • Type 2 Diabetes - Pipeline by Glucox Biotech AB, H1 2017
  • Type 2 Diabetes - Pipeline by GW Pharmaceuticals Plc, H1 2017
  • Type 2 Diabetes - Pipeline by Hadasit Medical Research Services & Development Ltd, H1 2017
  • Type 2 Diabetes - Pipeline by HanAll Biopharma Co Ltd, H1 2017
  • Type 2 Diabetes - Pipeline by Hanmi Pharmaceuticals Co Ltd, H1 2017
  • Type 2 Diabetes - Pipeline by Heptares Therapeutics Ltd, H1 2017
  • Type 2 Diabetes - Pipeline by HitGen LTD, H1 2017
  • Type 2 Diabetes - Pipeline by Hyundai Pharmaceutical Co Ltd, H1 2017
  • Type 2 Diabetes - Pipeline by Immuron Ltd, H1 2017
  • Type 2 Diabetes - Pipeline by Innopharmax Inc, H1 2017
  • Type 2 Diabetes - Pipeline by Innovative Targeting Solutions Inc, H1 2017
  • Type 2 Diabetes - Pipeline by Intarcia Therapeutics Inc, H1 2017
  • Type 2 Diabetes - Pipeline by Intas Pharmaceuticals Ltd, H1 2017
  • Type 2 Diabetes - Pipeline by Integral Molecular Inc, H1 2017
  • Type 2 Diabetes - Pipeline by Intercept Pharmaceuticals Inc, H1 2017
  • Type 2 Diabetes - Pipeline by Intrexon Corp, H1 2017
  • Type 2 Diabetes - Pipeline by Ionis Pharmaceuticals Inc, H1 2017
  • Type 2 Diabetes - Pipeline by Ironwood Pharmaceuticals Inc, H1 2017
  • Type 2 Diabetes - Pipeline by Islet Sciences Inc, H1 2017
  • Type 2 Diabetes - Pipeline by Japan Tobacco Inc, H1 2017
  • Type 2 Diabetes - Pipeline by Jeil Pharmaceutical Co Ltd, H1 2017
  • Type 2 Diabetes - Pipeline by Jenrin Discovery Inc, H1 2017
  • Type 2 Diabetes - Pipeline by JHL Biotech Inc, H1 2017
  • Type 2 Diabetes - Pipeline by Jiangsu Hansoh Pharmaceutical Group Co Ltd, H1 2017
  • Type 2 Diabetes - Pipeline by Jiangsu Hengrui Medicine Co Ltd, H1 2017
  • Type 2 Diabetes - Pipeline by Johnson & Johnson, H1 2017
  • Type 2 Diabetes - Pipeline by Kadimastem Ltd, H1 2017
  • Type 2 Diabetes - Pipeline by Kadmon Corp LLC, H1 2017
  • Type 2 Diabetes - Pipeline by Kareus Therapeutics SA, H1 2017
  • Type 2 Diabetes - Pipeline by Kissei Pharmaceutical Co Ltd, H1 2017
  • Type 2 Diabetes - Pipeline by Lead Discovery Center GmbH, H1 2017
  • Type 2 Diabetes - Pipeline by Leading BioSciences Inc, H1 2017
  • Type 2 Diabetes - Pipeline by Lexicon Pharmaceuticals Inc, H1 2017
  • Type 2 Diabetes - Pipeline by LG Chem, Ltd., H1 2017
  • Type 2 Diabetes - Pipeline by Ligand Pharmaceuticals Inc, H1 2017

List of Figures

  • Number of Products under Development for Type 2 Diabetes, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Number of Products by Top 10 Targets, H1 2017
  • Number of Products by Stage and Top 10 Targets, H1 2017
  • Number of Products by Top 10 Mechanism of Actions, H1 2017
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
  • Number of Products by Top 10 Routes of Administration, H1 2017
  • Number of Products by Stage and Top 10 Routes of Administration, H1 2017
  • Number of Products by Top 10 Molecule Types, H1 2017
  • Number of Products by Stage and Top 10 Molecule Types, H1 2017
Back to Top